P1-377 Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease

Shuan-Haim, Joshua R.; Pass, Mark D.; Patel, Suhas; Patel, Sameer; Lee, Paul; Smith, Juanita

doi:10.1016/s0197-4580(04)80689-4

Cited by 2 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study was published in a peer-reviewed journal (Tariot et al 2004). Three similar prospective studies have been published only in abstract format (Pass et al 2004; Patel et al 2004; Shua-Haim et al 2004). …”

Section: Resultsmentioning

confidence: 99%

“…Two studies were multicenter, randomized, double-blind, placebo-controlled (FLI 2003; Tariot et al 2004; Doody et al 2005), and three studies were open label (Pass et al 2004; Patel et al 2004; Shua-Haim et al 2004). The randomized, controlled trials (RCTs) (FLI 2003; Tariot et al 2004; Doody et al 2005) were not designed to determine the relative efficacy compared with placebo of memantine monotherapy, donepezil monotherapy, or combination therapy, but whether memantine would provide additional benefit in a patient already on a ChEI.…”

Section: Trial Designmentioning

confidence: 99%

“…Tariot et al (2004) randomized 203 patients to memantine and 201 to placebo. The sample sizes of the open studies varied from 12 to 25 (Pass et al 2004; Patel et al 2004; Shua-Haim et al 2004). Patient numbers were not available for one study (FLI 2003) except in a poster meta-analysis (n = 433) (Doody et al 2005).…”

Section: Trial Designmentioning

confidence: 99%

“…Tariot et al (2004) maintained patients on donepezil for at least 6 months, and at a stable dose of 5–10 mg daily for at least 3 months prior to the study. None of the open studies stated how long patients had been taking a ChEI before memantine was begun (Pass et al 2004; Patel et al 2004; Shua-Haim et al 2004). …”

Section: Trial Designmentioning

confidence: 99%

“…Diagnostic criteria were: National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association (NINCDS–ARDA) diagnosis of probable AD (FLI 2003; Tariot et al 2004; Doody et al 2005); DSM-IV (APA 1994); and NINCDS–ARDA for possible Alzheimer’s disease (Pass et al 2004; Patel et al 2004; Shua-Haim et al 2004). Disease stage ranged from mild to moderate AD in one RCT (FLI 2003; Doody et al 2005) to moderate to severe AD in the other (Tariot et al 2004).…”

Section: Trial Designmentioning

confidence: 99%

See 4 more Smart Citations

Memantine combined with an acetyl cholinesterase inhibitor ? hope for the future?

Fox

Maidment

Boustani

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer's disease (AD) is increasing. Objective: To assess the available data on the use of memantine-ChEI combination and to develop evidence-based recommendations. Method: A systematic literature review with detailed discussion of the current evidence base. Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine-ChEI combination is not significantly more effective than placebo-ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine-ChEI combination is significantly more effective than placebo-ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy. Conclusion:The available data do not justify the use of combination therapy. Future studies should include three arms (memantine-placebo, placebo-ChEI, and memantine-ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Trial Designmentioning

confidence: 99%

Section: Trial Designmentioning

confidence: 99%

Section: Trial Designmentioning

confidence: 99%

Section: Trial Designmentioning

confidence: 99%

See 3 more Smart Citations

Memantine combined with an acetyl cholinesterase inhibitor ? hope for the future?

Fox

Maidment

Boustani

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

show abstract

Benefits and Risks of Add-On Therapies for Alzheimer’s Disease

Magierski

Sobów

2015

Neurodegener. Dis. Manag.

View full text Add to dashboard Cite

Despite three decades of intensive research, the efforts of scientific society and industry and the expenditures, numerous attempts to develop effective treatments for Alzheimer's disease have failed. Currently, approved and widely used medications to treat cognitive deficits in Alzheimer's disease are symptomatic only and show at best modest efficacy. In this context, the need to develop a successful, disease-modifying treatment is loudly expressed. One way to achieve this goal is the use of add-on therapies or various combinations of existing 'conventional' drugs. Results of several clinical studies and post hoc analyses of combination therapy with all cholinesterase inhibitors and memantine are published. Moreover, there is a need for studies on long-term efficacy of combination therapy in Alzheimer's.

show abstract

P1-377 Safety, tolerability, and caregiver's impressions of combination therapy with rivastigmine and memantine for the treatment of Alzheimer's disease

Cited by 2 publications

References 0 publications

Memantine combined with an acetyl cholinesterase inhibitor ? hope for the future?

Memantine combined with an acetyl cholinesterase inhibitor ? hope for the future?

Benefits and Risks of Add-On Therapies for Alzheimer’s Disease

Contact Info

Product

Resources

About